About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Platelet Indices in Inflammatory Bowel Diseases | Clinical Trials | Clareo Health

Back to clinical trial search

Not Yet RecruitingNCT07320443

Platelet Indices in Inflammatory Bowel Diseases

Inflammatory bowel disease (IBD) is a chronic, immune-mediated condition characterized by relapsing inflammation of the gastrointestinal tract. It primarily includes two subtypes: ulcerative colitis (...

Lead sponsor: Assiut University•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Sahar Atef Ahmed

CONTACT

01040355329 saharatef519@gmail.com

Sponsors

Lead Sponsor

Assiut University

we aim to investigate the relationship between platelet indices (MPV, PDW, PCT, PLT) and disease activity in patients with inflammatory bowel disease. We also aim to evaluate the potential correlation between these platelet parameters and established inflammatory markers such as CRP, ESR, and fecal calprotectin. This may help clarify whether platelet indices can serve as accessible, cost-effective biomarkers in the clinical assessment of IBD

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Exclusion Criteria

•Hematologic malignancies or disorders.
•Pregnancy
•Use of antiplatelet or anticoagulant drugs

Related studies

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial

NCT06553053 · Crohn's Disease Relapse, Inflammatory Bowel Diseases

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

RECRUITINGPhase 2/3

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

NCT05986136 · Inflammatory Bowel Diseases

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

NCT06266663 · Inflammatory Bowel Diseases

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 6, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment84

Start dateDec 2025

Last updatedJan 6, 2026

Condition

Inflammatory Bowel Diseases

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions